China DNA Vaccine Market Size, Share & Trends Analysis Report by Type (Animal DNA Vaccine, Human DNA Vaccine) By Technology (Plasmid DNA Vaccine and Plasmid DNA Delivery) By Application (Oncology, Infectious Disease, and Others) Forecast period (2019-2025).
China DNA Vaccine market is anticipated to grow at a CAGR 42.8% during the forecast period. In China it is mandatory to inject the hepatitis B vaccine (HBV) and tuberculosis-TB (BCG) vaccine immediately to the child after birth as per Chinese law. China began its expanded program on Immunization (EPI) in 1992. It involves a mandatory 11-vaccine schedule which must be given to children from 0 to 6 years. The vaccination schedule is compulsory for Chinese citizens. The compulsory vaccines in the China are Hepatitis B (HBV), Japanese Encephalitis (JE) and Hepatitis A (HAV). Along with this, the recommended vaccines are Chickenpox, Rotavirus, and Rabies. China’s Food and Drug Administration (CFDA) under the CNRA issues vaccine-manufacturing had provided license to 34 companies that meet the required international manufacturing practice requirements.
Researchers in China have developed an inexpensive, stable DNA vaccine that can protect against two of the four known serotypes of dengue virus. According to the World Health Organization, the dengue virus is one of the most rapidly spreading mosquito-borne pathogens. A tetravalent dengue vaccine that protects against all four serotypes of dengue virus (DV1-4) has been approved for use in some countries.
The market is segmented on the basis of type, application and technology. Based on type, the market is segmented into animal DNA vaccine and human DNA vaccine. Based on technology, the market is segmented into plasmid DNA vaccine and plasmid DNA delivery. Based on application, the market is segmented into oncology, infectious disease and others.
The key market players that are active in the market include Beijing Advaccine Biotechnology Co., Eli Lilly and Co., GE Healthcare, Glaxosmithkline PLC., Inovio Pharmaceuticals Inc., Merck & Co., Novartis AG, Pfizer Inc., Roche Diagnostics GMBH and Sanofi Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.
Research Methodology:
The market study of the China DNA Vaccine market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
1. China DNA Vaccine Market Research and Analysis by Type
2. China DNA Vaccine Market Research and Analysis by Technology
3. China DNA Vaccine Market Research and Analysis by Application
The Report Covers:
China DNA Vaccine market is anticipated to grow at a CAGR 42.8% during the forecast period. In China it is mandatory to inject the hepatitis B vaccine (HBV) and tuberculosis-TB (BCG) vaccine immediately to the child after birth as per Chinese law. China began its expanded program on Immunization (EPI) in 1992. It involves a mandatory 11-vaccine schedule which must be given to children from 0 to 6 years. The vaccination schedule is compulsory for Chinese citizens. The compulsory vaccines in the China are Hepatitis B (HBV), Japanese Encephalitis (JE) and Hepatitis A (HAV). Along with this, the recommended vaccines are Chickenpox, Rotavirus, and Rabies. China’s Food and Drug Administration (CFDA) under the CNRA issues vaccine-manufacturing had provided license to 34 companies that meet the required international manufacturing practice requirements.
Researchers in China have developed an inexpensive, stable DNA vaccine that can protect against two of the four known serotypes of dengue virus. According to the World Health Organization, the dengue virus is one of the most rapidly spreading mosquito-borne pathogens. A tetravalent dengue vaccine that protects against all four serotypes of dengue virus (DV1-4) has been approved for use in some countries.
The market is segmented on the basis of type, application and technology. Based on type, the market is segmented into animal DNA vaccine and human DNA vaccine. Based on technology, the market is segmented into plasmid DNA vaccine and plasmid DNA delivery. Based on application, the market is segmented into oncology, infectious disease and others.
The key market players that are active in the market include Beijing Advaccine Biotechnology Co., Eli Lilly and Co., GE Healthcare, Glaxosmithkline PLC., Inovio Pharmaceuticals Inc., Merck & Co., Novartis AG, Pfizer Inc., Roche Diagnostics GMBH and Sanofi Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.
Research Methodology:
The market study of the China DNA Vaccine market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
1. China DNA Vaccine Market Research and Analysis by Type
2. China DNA Vaccine Market Research and Analysis by Technology
3. China DNA Vaccine Market Research and Analysis by Application
The Report Covers:
- Comprehensive Research Methodology of the China DNA Vaccine market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the China DNA Vaccine market.
- Insights about market determinants which are stimulating the China DNA Vaccine market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Companies Mentioned
A selection of companies mentioned in this report includes:
- Beijing Advaccine Biotechnology Co.
- Eli Lilly and Co.
- GE Healthcare
- Glaxosmithkline PLC.
- Inovio Pharmaceuticals Inc.
- Merck & Co.
- Novartis AG
- Pfizer Inc.
- Roche Diagnostics GMBH
- Sanofi Inc.
